IFN inhibition might be a suitable treatment for these severe organ involvement in SLE and data accumulated from monogenic interferonopathies could offer an argument for designing trials that are specific for severe organ involvement [26, 72]. Here, IFNA1 is linked to systemic lupus erythematosus.